Literature DB >> 21932315

Ectopia lentis as the presenting and primary feature in Marfan syndrome.

Neda Zadeh1, Jonathan A Bernstein, Anna Kaisa Niemi, Sarah Dugan, Andrea Kwan, David Liang, James C Hyland, H Eugene Hoyme, Louanne Hudgins, Melanie A Manning.   

Abstract

Marfan syndrome (MFS) is a multisystem connective tissue disorder with primary involvement of the ocular, cardiovascular, and skeletal systems. We report on eight patients, all presenting initially with bilateral ectopia lentis (EL) during early childhood. These individuals did not have systemic manifestations of MFS, and did not fulfill the revised Ghent diagnostic criteria. However, all patients had demonstratable, disease-causing missense mutations in the FBN1 gene. Based on molecular results, cardiovascular imaging was recommended and led to the identification of mild aortic root changes in seven of the eight patients. The remaining patient had mitral valve prolapse with a normal appearing thoracic aorta. The findings presented in this paper validate the necessity of FBN1 gene testing in all individuals presenting with isolated EL. As we observed, these individuals are at increased risk of cardiovascular complications. Furthermore, we also noted that the majority of our patient cohort's mutations occurred in the 5' portion of the FBN1 gene, and were found to affect highly conserved cysteine residues, which may indicate a possible genotype-phenotype correlation. We conclude that in patients with isolated features of EL, FBN1 mutation analysis is necessary to aid in providing prompt diagnosis, and to identify patients at risk for potentially life-threatening complications. Additionally, knowledge of the type and location of an FBN1 mutation may be useful in providing further clinical correlation regarding phenotypic progression and appropriate medical management.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21932315     DOI: 10.1002/ajmg.a.34245

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  8 in total

1.  A 2-Year-Old Child with Bilateral Ectopis Lentis and a Novel FBN1 Gene Variant Cys129Ser.

Authors:  Ahmed N Mohammad; Paldeep S Atwal
Journal:  J Pediatr Genet       Date:  2017-12-08

Review 2.  Molecular pathogenesis and management strategies of ectopia lentis.

Authors:  A Chandra; D Charteris
Journal:  Eye (Lond)       Date:  2014-01-10       Impact factor: 3.775

3.  Mutation analysis of FBN1 gene in two Chinese families with congenital ectopia lentis in northern China.

Authors:  Su-Zhen Tang; Ya-Ning Liu; Shao-Hua Hu; Hao Chen; Hui Zhao; Xue-Mei Feng; Xiao-Jing Pan; Peng Chen
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

Review 4.  Dental-craniofacial manifestation and treatment of rare diseases.

Authors:  En Luo; Hanghang Liu; Qiucheng Zhao; Bing Shi; Qianming Chen
Journal:  Int J Oral Sci       Date:  2019-02-20       Impact factor: 6.344

5.  Genotype variant screening and phenotypic analysis of FBN1 in Chinese patients with isolated ectopia lentis.

Authors:  Yijing Zhou; Dongwei Guo; Qianzhong Cao; Xinyu Zhang; Guangming Jin; Danying Zheng
Journal:  Mol Med Rep       Date:  2021-02-12       Impact factor: 2.952

6.  Novel p.G1344E mutation in FBN1 is associated with ectopia lentis.

Authors:  Yuan Yang; Ya-Li Zhou; Teng-Teng Yao; Hui Pan; Ping Gu; Zhao-Yang Wang
Journal:  Br J Ophthalmol       Date:  2020-05-13       Impact factor: 4.638

Review 7.  When flexibility is not necessarily a virtue: a review of hypermobility syndromes and chronic or recurrent musculoskeletal pain in children.

Authors:  Marco Cattalini; Raju Khubchandani; Rolando Cimaz
Journal:  Pediatr Rheumatol Online J       Date:  2015-10-06       Impact factor: 3.054

Review 8.  A scoping review presenting a wide variety of research on paediatric and adolescent patients with Marfan syndrome.

Authors:  Ingeborg Beate Lidal; Trine Bathen; Heidi Johansen; Gry Velvin
Journal:  Acta Paediatr       Date:  2020-02-17       Impact factor: 2.299

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.